BRADLEY, Ill. -- Australian biopharmaceutical company CSL announced Monday a major expansion at its Kankakee manufacturing facility, a move that will bring end-to-end plasma processing into the U.S.
Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0 ™ principles with sustainable design to transform plasma manufacturing Purpose-built to optimise the ...
The news: CSL has committed to a USD1.5 billion ($2.12 billion) expansion of its Illinois plasma therapy manufacturing facility, which it broke ground on Monday. The numbers: The Kankakee facility ...
CSL Plasma operates one of the world’s largest and most sophisticated plasma collection networks, with nearly 330 plasma donation centers globally, including the U.S. and Europe and employs nearly 16,000 employees. CSL Plasma is vertically integrated, meaning plasma collected at CSL Plasma facilities is used by CSL Behring for the sole purpose of manufacturing and delivering its life-saving ...
CSL consists of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Today, with the combined expertise of CSL Behring (with oversight to CSL Plasma), CSL Seqirus, and CSL Vifor—and our singular commitment to relentlessly innovate—CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they deserve. We’re always improving so life can, too.
CSL CSL is a global biopharma company working to create enduring impact for patients and public health. OUR GLOBAL MANUFACTURING AND OFFICE PRESENCE OUR BUSINESS US$15.6b in annual revenue 100+ countries that CSL provides lifesaving products to patients US$2.92 dividend per share for 2025 CSL uses its deep expertise in plasma-derived therapies, vaccines and biotechnology to deliver medicines ...
FiercePharma: CSL telegraphs 300 new hires as it breaks ground on $1.5B plasma-based medicine plant near Chicago
After teasing a plasma-based manufacturing expansion in the U.S. late last year, CSL is putting in the work and firming up details behind the $1.5 billion project. Monday, the Australian biopharma ...
CSL telegraphs 300 new hires as it breaks ground on $1.5B plasma-based medicine plant near Chicago
New $1.5 billion investment builds on over $3 billion already spent on CSL's U.S. operations since 2018 Expansion will create at least 300 new jobs and enhance production of plasma-derived therapies ...
Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...
Seeking Alpha: CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
FiercePharma: CSL gets top-line boost thanks to a post-pandemic boom in plasma collections
With plasma collection as its stock-in-trade, the struggles of CSL during the coronavirus lockdown were understandable. But a rebound—fueled by a surge in post-pandemic collections and an $11.7 ...
CSL gets top-line boost thanks to a post-pandemic boom in plasma collections
74-2967974 - CSL PLASMA INC. Entity Id: 74-2967974 Type: Foreign Profit Corporation Status: ACTIVE Registration date: 2001 Aug 23 Document Number: F01000004484 Last Event: NAME CHANGE AMENDMENT Event Date Filed: 05/01/2009 Adresses Principal Office Address: 900 Broken Sound Parkway, Ste 400, Boca Raton, FL 33487, changed: 05/30/2020 Mailing Address: 900 Broken Sound Parkway, Ste 400, Boca ...
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Together they help ensure people everywhere get the treatments they need.
CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients' needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas.
CSL offers Promising FUTURES, find yours here CSL was established in Australia in 1916. Over the ensuing years, CSL provided Australians with rapid access to 20th century medical advances including insulin and penicillin, and vaccines against influenza, polio and other infectious diseases. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides ...
CSL Behring CSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency.
ABC 7 Chicago: Biotechnology company to invest $1.5B in Illinois plasma-processing plan
Insider Monkey on MSN: Goldman Sachs adds Carlisle Companies (CSL) to conviction list, sees 2026 sales inflection
Carlisle Companies Incorporated (NYSE:CSL) is included among the 15 Cash-Rich Dividend Stocks to Invest in Right Now. Goldman Sachs made a notable move on April 1, adding Carlisle Companies ...
Goldman Sachs adds Carlisle Companies (CSL) to conviction list, sees 2026 sales inflection
FiercePharma: CSL Vifor proposes campaign to undo messaging about safety profile of rival product
CSL Vifor has proposed to launch a campaign that would undo the potentially misleading messages it sent about the safety of a rival product, the European Commission (EC) said. The initiative comes ...
CSL Vifor proposes campaign to undo messaging about safety profile of rival product
Carlisle Companies is positioned for strong growth, driven by aging U.S. commercial roofs and stricter energy standards. Find out why CSL stock is a buy.
Fast Lane Only on MSN: At a time of change, the 1972 BMW 3.0 CSL pushed performance forward
The 1972 BMW 3.0 CSL arrived at a moment when regulations, fuel crises and changing buyer tastes were reshaping performance cars, yet it managed to move the game on rather than retreat. By stripping ...
At a time of change, the 1972 BMW 3.0 CSL pushed performance forward
The quickest BMW (to date) around the Nürburgring has been revealed, but it's unclear if you can even buy it. On Thursday, the 2023 BMW M4 CSL broke cover. When production begins in July, only 1,000 ...
Over the past five decades of BMW M’s existence, it hasn’t made many CSL models. In fact, it’s only made three–the original BMW 3.0 CSL, the E46-gen M3 CSL, and the brand-new M4 CSL. That’s it. So you ...
The Drive: BMW E46 Owners: Don’t Sleep on Vorsteiner’s Carbon M3 CSL Body Kit